$JANX Climbs, $MYNZ Gains Momentum$JANX surges 48.8% to $59.86 on investor confidence in its cancer immunotherapy advancements. Similarly, $MYNZ’s rebound post-split positions it as a promising player in cancer diagnostics, offering a strong growth narrative.